Table3.
Clinical characteristics and outcomes after fecal microbiota transplantation in patients with recurrent Clostridioides difficile infection
| # | Sex | Age (y) | Diarrhea | Toxin A/B | Outcome | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| preFMT | postFMT | preFMT | postFMT | ||||||||||
| 2W | 8W | 24W | 48W | 2W | 8W | 24W | 48W | ||||||
| 1 | F | 92 | + | − | − | − | − | + | − | − | − | − | Clinical response |
| 2 | F | 52 | + | − | − | − | − | + | − | − | − | − | Clinical response |
| 3 | M | 50 | + | − | − | − | − | + | − | − | − | − | Clinical response |
| 4 | M | 86 | + | ND | − | ND | ND | + | ND | − | ND | ND | Clinical response |
#1, previous antibiotic treatment with metronidazole, vancomycin, and probiotics (miya-BM)
#2, previous antibiotic treatment with metronidazole and probiotics (bio-three)
#3, previous antibiotic treatment with metronidazole, vancomycin, and probiotics (biofermin and miya-BM)
#4, previous antibiotic treatment with metronidazole and probiotics (miya-BM)
FMT, fecal microbiota transplantation